Cargando…

REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis: A Canadian IBD Research Consortium Multicenter National Cohort Study

We aimed to evaluate the real-world effectiveness and safety of tofacitinib for the treatment of ulcerative colitis (UC). METHODS: REMIT-UC is a Canadian multicenter cohort study. Standardized data collection was performed on 334 consecutive adult outpatients with UC treated with tofacitinib. The pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Christopher, Panaccione, Remo, Xiao, Yasi, Khandelwal, Yuvan, Murthy, Sanjay K., Wong, Emily C.L., Narula, Neeraj, Tsai, Catherine, Peerani, Farhad, Reise-Filteau, Marica, Bressler, Brian, Starkey, Samantha Y., Loomes, Dustin, Sedano, Rocio, Jairath, Vipul, Bessissow, Talat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144270/ https://www.ncbi.nlm.nih.gov/pubmed/36580497 http://dx.doi.org/10.14309/ajg.0000000000002129

Ejemplares similares

Tofacitinib-Associated Iatrogenic Kaposi Sarcoma in a Patient With Ulcerative Colitis
por: Wetwittayakhlang, Panu, et al.
Publicado: (2021)

Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry
por: Agrawal, Manasi, et al.
Publicado: (2020)

Adenocarcinoma Within Carpet-Like Pseudopolyposis
por: Xiao, Yasi, et al.
Publicado: (2020)

The Great Debate With IBD Biosimilars: Con: Biosimilars Should Not Be Routinely Used as a First Line Biologic and Not Switched From Reference Biologics
por: Panaccione, Remo
Publicado: (2021)

Reliability of the Endoscopic Ultrasound Ulcerative Colitis (EUS-UC) score for assessment of inflammation in patients with ulcerative colitis
por: Yan, Brian M., et al.
Publicado: (2021)

Is There a Best First Line Biological/Small Molecule in IBD: Are We Ready for Sequencing?
por: Hahn, Gustavo Drügg, et al.
Publicado: (2022)

Cytomegalovirus and Inflammatory Bowel Diseases (IBD) with a Special Focus on the Link with Ulcerative Colitis (UC)
por: Jentzer, Alexandre, et al.
Publicado: (2020)

Fr098 IMPACT OF COVID-19 PANDEMIC IN IBD PATIENT CARE
por: Dahiya, Monica, et al.
Publicado: (2021)

The Impact of the COVID-19 Pandemic on IBD Care in Alberta: Patient and Provider Perspectives
por: Dahiya, Monica, et al.
Publicado: (2022)

Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials
por: Panaccione, Remo, et al.
Publicado: (2020)

Correction to: Characterization of Creatine Kinase Levels in Tofacitinib‑Treated Patients with Ulcerative Colitis: Results from Clinical Trials
por: Panaccione, Remo, et al.
Publicado: (2020)

Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey
por: Ma, Christopher, et al.
Publicado: (2017)

Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open‐label, long‐term extension study, OCTAVE open
por: Panaccione, Remo, et al.
Publicado: (2022)

A143 SAFETY OF BIOLOGICAL THERAPIES IN ELDERLY IBD: A SYSTEMATIC REVIEW
por: Golovics, P, et al.
Publicado: (2022)

Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB
por: Alexander, James L., et al.
Publicado: (2022)

Tofacitinib
Publicado: (2012)

IBD Subtype-Regulators IFNG and GBP5 Identified by Causal Inference Drive More Intense Innate Immunity and Inflammatory Responses in CD Than Those in UC
por: Gao, Sheng, et al.
Publicado: (2022)

Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme
por: Sandborn, William J, et al.
Publicado: (2022)

Implementing Cisco UCS solutions
por: Ahmed, Farhan, et al.
Publicado: (2013)

High Density UC Properties
por: Luigi B. TecchioLaboratori Nazionali di Legnaro
Publicado: (05/1)

UC Updatable Databases and Applications
por: Damodaran, Aditya, et al.
Publicado: (2020)

Sa127 AN IBD-RISK VARIANT IN PTPN2 PROMOTES CELLULAR UPTAKE OF SARS-COV-2, WHICH IS MITIGATED BY THE JAK INHIBITOR TOFACITINIB
por: Spalinger, Marianne, et al.
Publicado: (2021)

Antibody response to SARS-CoV-2 among individuals with IBD diminishes over time: a serosurveillance cohort study
por: Kaplan, Gilaad G, et al.
Publicado: (2022)

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
por: Panés, Julian, et al.
Publicado: (2017)

Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn’s Disease With a Loss of Response
por: Heron, Valerie, et al.
Publicado: (2022)

UC.183, UC.110, and UC.84 Ultra-Conserved RNAs Are Mutually Exclusive with miR-221 and Are Engaged in the Cell Cycle Circuitry in Breast Cancer Cell Lines
por: Corrà, Fabio, et al.
Publicado: (2021)

Erratum to Tofacitinib
Publicado: (2012)

The ENCODE Project at UC Santa Cruz
por: Thomas, Daryl J., et al.
Publicado: (2007)

Variation resources at UC Santa Cruz
por: Thomas, Daryl J., et al.
Publicado: (2007)

Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 2: Inactivated Vaccines
por: Jones, Jennifer L, et al.
Publicado: (2021)

Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 1: Live Vaccines
por: Benchimol, Eric I, et al.
Publicado: (2021)

Bile Salt Hydrolase-Competent Probiotics in the Management of IBD: Unlocking the “Bile Acid Code”
por: Gadaleta, Raffaella Maria, et al.
Publicado: (2022)

Isolated Small Bowel Amyloidosis
por: Ghaith, Jenan, et al.
Publicado: (2021)

Can we reduce bias in open-label trials when blinded outcome assessment is not possible? An example from the trigger trial
por: Kahan, Brennan, et al.
Publicado: (2015)

Bioequivalence of the pharmacokinetics between tofacitinib aspartate and tofacitinib citrate in healthy subjects
por: Shin, Wonsuk, et al.
Publicado: (2020)

Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19
por: Maslennikov, Roman, et al.
Publicado: (2021)

Analysis of Long Non-Coding RNA (lncRNA) uc.38 and uc.63 Expression in Breast Carcinoma Patients
por: Zadrożna-Nowak, Anna, et al.
Publicado: (2022)

Management of inflammatory bowel disease with Clostridium difficile infection
por: D’Aoust, Julie, et al.
Publicado: (2017)

Disease monitoring strategies in inflammatory bowel diseases: What do we mean by “tight control”?
por: Gonczi, Lorant, et al.
Publicado: (2019)

Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules
por: Verdon, Christine, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8kfgshde30c158g7u0433nua93